pharmaceutical industry

Biden says other companies will slash insulin prices after Eli Lilly move

Reuters

This is AI generated summarization, which may have errors. For context, always refer to the full article.

Biden says other companies will slash insulin prices after Eli Lilly move

INSULIN. Boxes of the drug Humalog, made by Eli Lilly and Company, sit on a counter at a pharmacy in Provo, Utah, January 9, 2020.

George Frey/Reuters

Eli Lilly will cut list prices by 70% for its most commonly prescribed insulin products, Humalog and Humulin, starting in the fourth quarter of 2023

BALTIMORE, USA – US President Joe Biden said on Wednesday, March 1, that other pharmaceutical companies will have to lower their insulin prices in the wake of Eli Lilly’s decision to slash its prices for the popular diabetes treatment.

Eli Lilly said on Wednesday it will cut list prices by 70% for its most commonly prescribed insulin products, Humalog and Humulin, beginning from the fourth quarter of this year.

“Guess what that means?” Biden told Democrats gathered in Baltimore for an annual retreat. “Every other company making it, someone’s gonna have to lower their price.”

Biden’s signature legislative achievement, the Inflation Reduction Act, has capped insulin prices for Medicare recipients at $35 per month but the law does not extend to patients with private insurance or without insurance from higher prices. He wants Congress to extend the cap beyond Medicare.

“Once you expose these things, it’s awful hard to defend it,” Biden told reporters at the White House before leaving for Baltimore. “Once one major carrier or one major operator changes it, it changes everything. So I think we’ve made a lot of progress.” – Rappler.com

Add a comment

Sort by

There are no comments yet. Add your comment to start the conversation.

Summarize this article with AI

How does this make you feel?

Loading
Download the Rappler App!